ApoE and Alzheimer’s Disease

Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. Chung, W. S., Verghese, P. B., Chakraborty, C., Joung, J., Hyman, B. T., Ulrich, J. D., Holtzman, D. M., & Barres, B. A. (2016). Proceedings of the National Academy of Sciences of the United States of America113(36), 1018610191.

APOE genotype and sex affect microglial interactions with plaques in Alzheimer’s disease mice. Stephen. T. L., Cacciottolo, M., Balu, D., Morgan, T. E., LaDu, M. J., Finch, C. E., & Pike, C. J. (2019). Acta neuropathologica communications, 7(1), 82.

Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau. Kang, S. S., Ebbert, M., Baker, K. E., Cook, C., Wang, X., Sens, J. P., Kocher, J. P., Petrucelli, L., & Fryer, J. D. (2018).  The Journal of experimental medicine215(9), 22352245.

ApoE4 Accelerates Early Seeding of Amyloid Pathology. Liu, C. C., Zhao, N., Fu, Y., Wang, N., Linares, C., Tsai, C. W., & Bu, G. (2017). Neuron96(5), 10241032.

Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes. Zhao, N., Liu, C. C., Van Ingelgom, A. J., Martens, Y. A., Linares, C., Knight, J. A., Painter, M. M., Sullivan, P. M., & Bu, G. (2017).  Neuron96(1), 115129.

Association of APOE with tau-tangle pathology with and without β-amyloid. Farfel J.M., Yu L., De Jager P.L., Schneider J.A., Bennett D.A. (2016) Neurobiol Aging, 37:1925.

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010).  Annals of neurology67(1), 122131.

apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008).  The Journal of clinical investigation118(12), 40024013.

APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease. Youmans, K. L., Tai, L. M., Nwabuisi-Heath, E., Jungbauer, L., Kanekiyo, T., Gan, M., Kim, J., Eimer, W. A., Estus, S., Rebeck, G. W., Weeber, E. J., Bu, G., Yu, C., & Ladu, M. J. (2012).  The Journal of biological chemistry287(50), 4177441786.

Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. Liao, F., Li, A., Xiong, M., Bien-Ly, N., Jiang, H., Zhang, Y., Finn, M. B., Hoyle, R., Keyser, J., Lefton, K. B., Robinson, G. O., Serrano, J. R., Silverman, A. P., Guo, J. L., Getz, J., Henne, K., Leyns, C. E., Gallardo, G., Ulrich, J. D., Sullivan, P. M., Holtzman, D. M. (2018).  The Journal of clinical investigation128(5), 21442155.

Lack of hepatic apoE does not influence early Aβ deposition: observations from a new APOE knock-in model. Huynh, T. V., Wang, C., Tran, A. C., Tabor, G. T., Mahan, T. E., Francis, C. M., Finn, M. B., Spellman, R., Manis, M., Tanzi, R. E., Ulrich, J. D., & Holtzman, D. M. (2019).  Molecular neurodegeneration14(1), 37.

A flow cytometry-based in vitro assay reveals that formation of apolipoprotein E (ApoE)-amyloid beta complexes depends on ApoE isoform and cell type. Kara, E., Marks, J. D., Roe, A. D., Commins, C., Fan, Z., Calvo-Rodriguez, M., Wegmann, S., Hudry, E., & Hyman, B. T. (2018). The Journal of biological chemistry293(34), 1324713256.

ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L.,  Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., Rojas, J. C., Gallardo, G., Wang, K., Roh, J., Robinson, G., Finn, M. B., Jiang, H., Sullivan, P. M., Baufeld, C., Wood, M. W., Sutphen, C., Holtzman, D. M. (2017). Nature549(7673), 523527.

APOE ε2 is associated with increased tau pathology in primary tauopathy. Zhao, N., Liu, C. C., Van Ingelgom, A. J., Linares, C., Kurti, A., Knight, J. A., Heckman, M. G., Diehl, N. N., Shinohara, M., Martens, Y. A., Attrebi, O. N., Petrucelli, L., Fryer, J. D., Wszolek, Z. K., Graff-Radford, N. R., Caselli, R. J., Sanchez-Contreras, M. Y., Rademakers, R., Murray, M. E., Koga, S., Bu, G. (2018).  Nature communications9(1), 4388.

Apolipoprotein E decreases tau kinases and phospho-tau levels in primary neurons. Hoe, H. S., Freeman, J., & Rebeck, G. W. (2006).  Molecular neurodegeneration1, 18.

Genetic perturbations of disease risk genes in mice capture transcriptomic signatures of late-onset Alzheimer’s disease. Pandey RS, Graham L, Uyar A, Preuss C, Howell GR, Carter GW.  Mol Neurodegener. 2019 Dec 26;14(1):50.

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF. Cicognola C, Chiasserini D, Eusebi P, Andreasson U, Vanderstichele H, Zetterberg H, Parnetti L, Blennow K.  Mol Neurodegener. 2016 Sep 7;11(1):65.

Lack of hepatic apoE does not influence early Aβ deposition: observations from a new APOE knock-in model. Huynh TV, Wang C, Tran AC, Tabor GT, Mahan TE, Francis CM, Finn MB, Spellman R, Manis M, Tanzi RE, Ulrich JD, Holtzman DM.  Mol Neurodegener. 2019 Oct 17;14(1):37.

Apolipoprotein E lipoprotein particles inhibit amyloid-β uptake through cell surface heparan sulphate proteoglycan. Fu Y, Zhao J, Atagi Y, Nielsen HM, Liu CC, Zheng H, Shinohara M, Kanekiyo T, Bu G.  Mol Neurodegener. 2016 May 5;11(1):37.

APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice. Pankiewicz JE, Baquero-Buitrago J, Sanchez S, Lopez-Contreras J, Kim J, Sullivan PM, Holtzman DM, Sadowski MJ.  Mol Neurodegener. 2017 Jan 31;12(1):12.

Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease. Rangaraju S, Dammer EB, Raza SA, Rathakrishnan P, Xiao H, Gao T, Duong DM, Pennington MW, Lah JJ, Seyfried NT, Levey AI. Mol Neurodegener. 2018 May 21;13(1):24.